These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34501216)

  • 1. Sex Differences in the Clinical Features and Outcomes of Patients with Acute Coronary Syndrome Treated with Two Generations (Absorb and Magmaris) of Bioresorbable Vascular Scaffolds.
    Włodarczak A; Rola P; Szudrowicz M; Łanocha M; Barycki M; Kulczycki JJ; Gosiewska A; Turkiewicz K; Lesiak M; Doroszko A
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome.
    Włodarczak A; Łanocha M; Szudrowicz M; Barycki M; Gosiewska A; Kulczycki JJ; Lesiak M; Doroszko A; Rola P
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice.
    Rola P; Włodarczak A; Łanocha M; Barycki M; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Gosiewska A; Woźnica K; Lesiak M; Doroszko A
    Cardiol J; 2022 May; 30(6):870-80. PubMed ID: 35621089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
    Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort.
    Włodarczak A; Rola P; Barycki M; Furtan Ł; Łanocha M; Włodarczak S; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Kędzierska M; Giniewicz K; Doroszko A; Lesiak M
    Diab Vasc Dis Res; 2023; 20(4):14791641231188705. PubMed ID: 37439002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions.
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Giniewicz K; Łanocha M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Włodarczak P; Doroszko A; Lesiak M
    J Pers Med; 2024 May; 14(5):. PubMed ID: 38793122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnesium bioresorbable scaffold (Magmaris) versus polymer biodegradable ultrathin drug-eluting stent (Ultimaster) in acute coronary syndrome. Mid-term outcomes (2 years).
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Doroszko A; Lesiak M
    Postepy Kardiol Interwencyjnej; 2024 Mar; 20(1):67-75. PubMed ID: 38616930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population-12-Month Clinical Outcome.
    Rola P; Włodarczak A; Włodarczak S; Barycki M; Szudrowicz M; Łanocha M; Furtan Ł; Woźnica K; Kulczycki JJ; Jaroszewska-Pozorska J; Kędzierska M; Doroszko A; Lesiak M
    J Interv Cardiol; 2022; 2022():5223317. PubMed ID: 36605917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent.
    Barkholt TØ; Webber B; Holm NR; Ormiston JA
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):E674-E682. PubMed ID: 31710149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnesium versus poly-L-lactic acid bioresorbable scaffolds: in vivo optical coherence tomography comparison of mechanical performance.
    Abellás-Sequeiros RA; Ocaranza-Sanchez R; Galvaõ-Braga C; Marques J; Gonzalez-Juanatey C
    Arch Cardiol Mex; 2020; 90(1):8-15. PubMed ID: 31996867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds-Insights From an All-Comer Registry.
    Bossard M; Madanchi M; Avdijaj D; Attinger-Toller A; Cioffi GM; Seiler T; Tersalvi G; Kobza R; Schüpfer G; Cuculi F
    Front Cardiovasc Med; 2022; 9():856930. PubMed ID: 35498044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold.
    Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
    Tijssen RYG; van der Schaaf RJ; Kraak RP; Vink MA; Hofma SH; Arkenbout EK; Weevers APJD; Kerkmeijer LSM; Onuma Y; Serruys PW; Beijk MAM; Koch KT; Baan J; Vis MM; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):89-96. PubMed ID: 30968559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Absorb bioresorbable scaffold implantation in acute coronary syndrome.
    Rzeszutko Ł; Węgiel M; Kleczyński P; Zasada W; Depukat R; Rakowski T; Legutko J; Surdacki A; Dudek D; Bartuś S
    Kardiol Pol; 2018; 76(10):1434-1440. PubMed ID: 30067276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model.
    Waksman R; Lipinski MJ; Acampado E; Cheng Q; Adams L; Torii S; Gai J; Torguson R; Hellinga DM; Westman PC; Joner M; Zumstein P; Kolodgie FD; Virmani R
    Circ Cardiovasc Interv; 2017 Aug; 10(8):. PubMed ID: 28801538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of acute versus stable coronary syndrome in patients treated with the Magmaris scaffold: Two-year results from the Magmaris Multicenter Italian Registry.
    Galli S; Troiano S; Palloshi A; Rapetto C; Pisano F; Aprigliano G; Leoncini M; Ravagnani P; Del Maestro M; Montorsi P
    Cardiovasc Revasc Med; 2023 Dec; 57():53-59. PubMed ID: 37543502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Mechanical Performance of Magmaris vs. DESolve Bioresorbable Scaffolds in a Real-World Scenario.
    Boeder NF; Dörr O; Koepp T; Blachutzik F; Achenbach S; Elsässer A; Hamm CW; Nef HM
    Front Cardiovasc Med; 2021; 8():696287. PubMed ID: 34195239
    [No Abstract]   [Full Text] [Related]  

  • 19. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.
    Byrne RA; Alfonso F; Schneider S; Maeng M; Wiebe J; Kretov E; Bradaric C; Rai H; Cuesta J; Rivero F; Hoppmann P; Schlichtenmaier J; Christiansen EH; Cassese S; Joner M; Schunkert H; Laugwitz KL; Kastrati A
    Eur Heart J; 2019 Jan; 40(2):167-176. PubMed ID: 30520980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 12-month clinical outcomes after Magmaris percutaneous coronary intervention in a real-world cohort of patients: Results from the CardioHULA registry.
    Abellas-Sequeiros RA; Ocaranza-Sanchez R; Bayon-Lorenzo J; Santas-Alvarez M; Gonzalez-Juanatey C
    Rev Port Cardiol (Engl Ed); 2020 Aug; 39(8):421-425. PubMed ID: 32763098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.